AC Immune SA (ACIU) vs Nautilus Biotechnology (NAUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed AC Immune SA (ACIU) over the past year, gaining 126.3% versus a loss of 28.4%. Over five years, ACIU leads with a -58.4% price change compared with -65.7% for NAUT. AC Immune SA is the larger company by market cap ($256.5 million vs $236.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | NAUT |
|---|---|---|
| Share price | $2.58 | $1.86 |
| Market cap | $256.52M | $236.69M |
| 1-day change | +0.39% | -5.10% |
| YTD return | -18.15% | +0.51% |
| 1-year return | -28.41% | +126.33% |
| 5-year return | -58.41% | -65.67% |
| Forward P/E | 4.33 | — |
| EPS (TTM) | $-0.54 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $4.31 |
| 52-week low | $2.10 | $0.82 |
| Distance from 52-week high | -35.50% | -56.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +230.23% | +105.91% |
| Average volume | 202.76K | 2.59M |
| Shares outstanding | 99.43M | 127.26M |
| Employees | 90 | 127 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NAUT has outperformed ACIU by 154.7 percentage points over the past year.
- The two companies sit in different sectors: AC Immune SA in Health Care and Nautilus Biotechnology in Industrials.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
ACIU vs NAUT FAQ
Which is bigger, AC Immune SA or Nautilus Biotechnology?
AC Immune SA (ACIU) is larger, with a market capitalization of $256.52M compared with $236.69M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, ACIU or NAUT?
NAUT returned +126.33% over the past 12 months, compared with -28.41% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Nautilus Biotechnology in the same industry?
No. AC Immune SA is in the Health Care sector, while Nautilus Biotechnology is in Industrials.